Another Drug Company Files New Lawsuit to Undermine Medicare’s Ability to Negotiate Lower Drug Prices Under Inflation Reduction Action

Ciscomani Publicly Opposed Inflation Reduction Act Before Taking Office, Supports Plan to Eliminate Drug Price Negotiation

TUCSON —  The Inflation Reduction Act's wildly popular Medicare drug price negotiation provision is under attack from Republicans in Congress like Juan Ciscomani who opposed the law before taking office against it, as well as pharmaceutical companies who are now suing to overturn the law.

The drug manufacturer, Novartis, filed suit in the Ninth Circuit to overturn the law this week after the Biden administration announced that one of its medications—heart failure drug Entresto—would be targeted for price negotiation.

Ciscomani, who sits on the Republican Study Committee, supported a budget released this summer that would undermine Medicare’s ability to negotiate drug prices.

“Big Pharma and Congressman Ciscomani are trying to undermine the Inflation Reduction Act and force Arizona Medicare patients to keep paying the highest out-of-pocket costs in the world for their prescription drugs,” said Honest Arizona executive director Andrea Moreno. “It’s time for Congressman Ciscomani to keep his promise to Arizonans and side with them, not Big Pharma.”

###